首页|Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba

Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba

扫码查看
原文链接
  • 万方数据
  • 维普
Bioactive compounds derived from herbal medicinal plants modulate various therapeutic tar-gets and signaling pathways associated with cardiovascular diseases(CVDs),the world's primary cause of death.Ginkgo biloba,a well-known traditional Chinese medicine with notable cardiovascular actions,has been used as a cardio-and cerebrovascular therapeutic drug and nutraceutical in Asian countries for centuries.Preclinical studies have shown that ginkgolide B,a bioactive component in Ginkgo biloba,can ameliorate atherosclerosis in cultured vascular cells and disease models.Of clinical relevance,several clinical trials are ongoing or being completed to examine the efficacy and safety of ginkgolide B-related drug preparations in the prevention of cerebrovascular diseases,such as ischemia stroke.Here,we present a comprehensive review of the pharmacological activities,pharmacokinetic characteristics,and mecha-nisms of action of ginkgolide B in atherosclerosis prevention and therapy.We highlight new molecular targets of ginkgolide B,including nicotinamide adenine dinucleotide phosphate oxidases(NADPH oxi-dase),lectin-like oxidized LDL receptor-1(LOX-1),sirtuin 1(SIRT1),platelet-activating factor(PAF),proprotein convertase subtilisin/kexin type 9(PCSK9)and others.Finally,we provide an overview and discussion of the therapeutic potential of ginkgolide B and highlight the future perspective of developing ginkgolide B as an effective therapeutic agent for treating atherosclerosis.

Cardiovascular diseaseAtherosclerosisGinkgo bilobaGinkgolide BEndothelial dysfunctionLOX-1PCSK9PAF-R antagonist

Weile Ye、Jiaojiao Wang、Peter J.Little、Jiami Zou、Zhihua Zheng、Jing Lu、Yanjun Yin、Hao Liu、Dongmei Zhang、Peiqing Liu、Suowen Xu、Wencai Ye、Zhiping Liu

展开 >

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education(MOE)of China,Jinan University,Guangzhou 510632,China

Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research,College of Pharmacy,Jinan University,Guangzhou 510632,China

State Key Laboratory of Bioactive Molecules and Druggability Assessment,Jinan University,Guangzhou 510632,China

Pharmacy Australia Centre of Excellence,School of Pharmacy,University of Queensland,Woolloongabba QLD 4102,Australia

Sunshine Coast Health Institute and School of Health and Behavioural Sciences,University of the Sunshine Coast,Birtinya QLD 4575,Australia

National-Local Joint Engineering Lab of Druggability and New Drugs Evaluation,Guangdong Provincial Key Laboratory of New Drug Design and Evaluation,Sun Yat-sen University,Guangzhou 510006,China

School of Pharmacy,Bengbu Medical College,Bengbu 233030,China

Institute of Endocrine and Metabolic Diseases,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230026,China

展开 >

国家自然科学基金国家自然科学基金国家自然科学基金国家自然科学基金国家自然科学基金国家自然科学基金National Mega-Project for Innovative DrugsLocal Innovative and Research Teams Project of Guangdong Pearl River Talents ProgramLocal Innovative and Research Teams Project of Guangdong Pearl River Talents ProgramNational Engineering and Technology Research Center for New drug Druggability Evaluation Seed Program of Guangdong Province

82270500818703248220330482070464U1401225U21A204192019ZX097350022017BT01Y0362017BT01Y0932017B090903004

2024

10.1016/j.apsb.2023.09.014

药学学报(英文版)

药学学报(英文版)

CSTPCD
ISSN：
年,卷(期)：2024.14(1)
  • 224